Fees, statements, and processor pricing — explained plainly.

Peptides sit in a regulatory gray zone the major card networks have flagged for years.

Online gaming is one of the most heavily regulated categories on the card networks.

Adult creator platforms combine two categories the card networks treat as high-risk: adult content and subscription billing with elevated chargeback rates.

CBD became federally legal at the hemp level in 2018, but card brands and aggregators still treat it as high-risk because of evolving FDA guidance, state-by-state restrictions, and confusion with cannabis.

Supplements draw high-risk classification because of free-trial billing models, continuity programs, weight-loss and male-enhancement claims, and FTC enforcement history.

Vape products are restricted at the federal level (PACT Act, FDA deeming rules) and many state levels.

Adult content is one of the original high-risk verticals on the card networks.

Kratom is legal federally but restricted or banned in several states, and the FDA has issued repeated warnings about the category.

Forex, crypto, and online trading platforms combine high transaction values, cross-border activity, and complex regulatory exposure (FinCEN, MSB licensing, MiFID, FCA).

Subscription boxes face elevated chargeback rates from friendly fraud, forgotten renewals, and recurring-billing disputes.

Firearms and tactical sales involve federal licensing (FFL), age restrictions, and shipping rules that vary by state.

Debt relief and credit repair are heavily regulated by the FTC (Telemarketing Sales Rule, CROA) and state attorneys general.

Secondary ticket sales sit in a high-risk bucket because chargebacks spike around cancellations, postponements, and 'event of the year' games where buyers regret prices.

Even non-operator gambling sites — picks services, prediction subscriptions, betting tips — get classified as high-risk because acquirers worry about regulatory exposure, refund disputes, and the optical risk of processing for anything gambling-adjacent.

Telemedicine, hormone therapy, and direct-to-consumer clinics are high-risk because of state-by-state physician licensing, controlled-substance scheduling, recurring prescription billing, and the regulatory overlap between healthcare and ecommerce.